Clinical observation of recombinant human erythropoietin on chemotherapy-induced anemia in patients with gastrointestinal cancer

ZHAO Cheng-min; HUANG Dai-fa; ZHANG Li-hui; CAO Yu-hua; CHE Hai-long

Abstract：Objective:To evaluate the efficacy and safety of recombinant human erythropoietin (rhEPO)in the treatment of chemotherapy-induced anemia in patients with gastrointestinal cancer.Methods:Eighty patients with bone marrow supression after chemotherapy for gastrointestinal malignant tumor were divided into two groups by random number table according to their conditions.The treatment group was treated with recombinant human erythropoietin and iron preparations,while the control group only received iron preparations.The changes of hemoglobin,red blood cells,KPS score and adverse reactions were observed.Results:The clinical effective rates of the treatment group and the control group were 97.5％ and 25％,respectively,for which the treatment group was statistically significantly higher than the control group (P ＜ 0.05).After 4 weeks of treatment,the hemoglobin [(136 ± 12.25) g· L-1] and hematocrit [(36.87 ± 5.12)] of the treatment group had statistically significant difference with those of the control group [(90.60 ± 12.26) g· L-1 and (26.35 ± 3.28)] (P ＜ 0.05).The KPS score was significantly im-proved after treatment compared between the two groups,which showed that the quality of life of patients improved,and the two groups had statistical significance (P ＜ 0.05).There was 1 case of elevated blood pressure in the treatment group and the control group respectively,but the difference was not statistically significant (P ＞ 0.05).Conclusion:Recombinant human erythropoietin can effectively correct chemotherapyinduced anemia in patients with gastrointestinal malignancies rapidly,thus ensure the normal chemotherapy,and the incidence of adverse reactions is low.It is worthy of clinical application.